No insider purchase over the last 90 days. The latest, by 이원석, was filed 29 May 2026.
Daehan Nupharm Co.,Ltd.: what insiders have been doing
Daehan Nupharm Co.,Ltd. is a Health Care company. Its directors and officers file their transactions with DART (FSS). 2 insiders have disclosed 6 filings since 2 November 2025.
Not one open-market sale was filed. On the buying side, 2 insiders reported 3 purchases totalling €33k. The amount is not disclosed for 2 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 chief executive among the declarants. 이원석 filed the largest purchase, €33k, on 29 May 2026, which represents 0.066% of the company's market value.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 6 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 5 purchases against no sales.
The last insider purchase was made public on 29 May 2026, 165 days ago. Typically, a trade is published a median of 3 days after it takes place. This delay matters because a trade only becomes useful information once it is public.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -12.8%Entry ₩5,850 · Close 30 Oct 2026 ₩5,100
- -24.7%Entry ₩6,770 · Close 30 Oct 2026 ₩5,100
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 9,166 shares@ ₩6,227.63690.066% mcap100.0% of flowShareKRXDART:20260529000062Canonical exit: 27 Aug 2026 (T+90)
- KRXDART:20260529000075
- 40,834 sharesShareKRXDART:20260526000306Canonical exit: 24 Aug 2026 (T+90)
- ●Executives0DART
- 0KRXDART:20260402002483
- 20,400 sharesKRXDART:20260211000655Canonical exit: 7 May 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20241121000299
- 37,365 sharesKRXDART:20241014000202Canonical exit: 2 Jan 2025 (T+90)
- ShareKRXDART:20240830000604Canonical exit: 27 Nov 2024 (T+90)
- 0KRXDART:20240813000701
- 0KRXDART:20240521000026
- 0KRXDART:20240516000709
- 0KRXDART:20240513000340
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20231116000174
- 0KRXDART:20230914000138
- 0KRXDART:20230821000426
- 0KRXDART:20230807000348
- 0KRXDART:20230623000405
- 0KRXDART:20230517000240
25 of 48 declarations
About Daehan Nupharm Co.,Ltd.
대한뉴팜 is a company in the healthcare and pharmaceutical sector, listed on the XKRX exchange. It specializes in the development and marketing of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
